ACM
NBSE

AIGH Capital Management’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

AIGH Capital Management’s Portfolio NBSE Stock Details NBSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-43,601
Closed -$345K – 61
2022
Q3 		$345K Sell
43,601
-7,778
-15% -$129K 0.11% 43
2022
Q2 		$1.08M Hold
51,379
– – 0.28% 35
2022
Q1 		$1.93M Buy
51,379
+1,365
+3% +$47.2K 0.47% 27
2021
Q4 		$2.81M Buy
+50,014
New +$3.36M 0.86% 28

Other funds holding NBSE

GC
Greenlight Capital New York $2.05B AUM 78.75% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CMU
Carnegie Mellon University Pittsburgh, Pennsylvania $78.9M AUM 38.67% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
KAS
Kestra Advisory Services Austin, Texas $31B AUM 28.39% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return
JAMONY
Jacob Asset Management of New York Hermosa Beach, California $70.9M AUM 14.28% 1-Year Est. Return
PCM
Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

AIGH Capital Management's NBSE Position: Q4 2022 in Review

AIGH Capital Management sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q4 2022, closing a stake of 43,601 shares — an estimated $345K sold.

AIGH Capital Management first reported a position in NBSE in Q4 2021 and held it in 4 quarters. The position peaked at $2.81M in Q4 2021. 34 funds tracked by Wall St. Rank hold NBSE as of Q4 2022.

  • AIGH Capital Management reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • AIGH Capital Management sold 43,601 NeuBase Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $345K.
  • AIGH Capital Management first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2021 and held it in 4 quarters.
  • AIGH Capital Management's NeuBase Therapeutics, Inc. Common Stock position peaked at $2.81M in Q4 2021.
  • 34 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q4 2022.

Based on AIGH Capital Management's 13F filing for Q4 2022, filed 15 Feb 2023.